The National Institute for Health and Clinical Excellence (NICE) says a combination of Thalidomide, an alkylating agent and a corticosteroid as they delay the disease’s progression and improve patient life expectancy. The combination is to be used in patients for whom chemotherapy is deemed unsafe or inappropriate.
The lack of a cure for this type of cancer means that any new treatments are going to be beneficial to the 4,000 people who are diagnosed annually. The price of £2,100 per treatment cycle of Thalidomide is also significantly less than similar treatments.
The NICE recommendation should mean that Celgene’s drug is used to treat those with multiple myeloma soon.
Looking for a job in the pharmaceutical industry? Start by clicking here, now